Neuropsychiatric Symptoms in People With Korsakoff Syndrome and Other Alcohol-Related Cognitive Disorders Living in Specialized Long-Term Care Facilities: Prevalence, Severity, and Associated Caregiver Distress

2018 ◽  
Vol 19 (3) ◽  
pp. 240-247 ◽  
Author(s):  
Ineke J. Gerridzen ◽  
Cees M.P.M. Hertogh ◽  
Marja F. Depla ◽  
Ruth B. Veenhuizen ◽  
Els M.L. Verschuur ◽  
...  
Keyword(s):  
Long Term Care ◽  
Neuropsychiatric Symptoms ◽  
Cognitive Disorders ◽  
Caregiver Distress ◽  
Term Care ◽  
Korsakoff Syndrome ◽  
Care Facilities

scholarly journals Does paracetamol improve quality of life, discomfort, pain and neuropsychiatric symptoms in persons with advanced dementia living in long-term care facilities? A randomised double-blind placebo-controlled crossover (Q-PID) trial

BMC Medicine ◽  
2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Paulien H. van Dam ◽  
Wilco P. Achterberg ◽  
Bettina S. Husebo ◽  
Monique A. A. Caljouw
Keyword(s):  
Long Term Care ◽  
Pain Treatment ◽  
Neuropsychiatric Symptoms ◽  
Study Medication ◽  
Advanced Dementia ◽  
Double Blind ◽  
Term Care ◽  
Care Facilities

Abstract Background The objectives of this study are to determine the effects of regularly scheduled administration of paracetamol (acetaminophen) on quality of life (QoL), discomfort, pain and neuropsychiatric symptoms of persons with dementia living in long-term care facilities (LTCFs). Methods A multicentre randomised double-blind placebo-controlled crossover trial for 13 weeks (January 2018 to June 2019) in 17 LTCFs across the west of the Netherlands. Inclusion criteria were age ≥ 65 years, (advanced) dementia and a moderate to low QoL, independent of the presence of pain (QUALIDEM ≤ 70). Exclusion criteria were the use of regular pain treatment, allergies to the study medication, severe liver disease, use of > 4 units of alcohol/day, weight < 50 kg and/or concomitant use of flucloxacillin. Participants received study medication (paracetamol/placebo) in two periods of 6 weeks each (1 week in between as a wash-out period). Randomisation decided in which order participants received paracetamol and placebo. Primary outcomes included QoL (QUALIDEM) and discomfort (DS-DAT), secondary outcomes included pain (MOBID-2) and neuropsychiatric symptoms (NPI-NH). Results Ninety-five LTCF residents (mean age 83.9 years [SD 7.6], 57.9% females) were included. Repeated linear mixed models showed no difference in mean differences of QUALIDEM (paracetamol +1.3 [95% CI -1.0–3.5], placebo +1.5 [95% CI -0.7–3.8]), DS-DAT (paracetamol -0.1 [95% CI -1.4–1.2], placebo 0.6 [95 CI -0.7–1.8]), MOBID-2 (paracetamol 0.0 [95% CI -0.5–0.5], placebo -0.2 [95% CI -0.7–0.3]) and NPI-NH (paracetamol +1.5 [95% CI -2.3–5.4], placebo -2.1 [95% CI -6.0–1.7]) in favour of either paracetamol or placebo. Conclusions Compared to placebo, paracetamol showed no positive effect on QoL, discomfort, pain and neuropsychiatric symptoms in persons with advanced dementia with low QoL. It is important to find out more specifically which individual persons with advanced dementia could benefit from pain treatment with paracetamol, and for clinicians to acknowledge that a good assessment, monitoring and multidomain approach is vital for improving QoL in this vulnerable group. Trial registration Netherlands Trial Register NTR6766. Trial registration date: 20 October 2017

scholarly journals Health workers perception on telemedicine in management of neuropsychiatric symptoms in long-term care facilities: Two years follow-up

2020 ◽  
Vol 41 (6) ◽  
pp. 1000-1005
Author(s):  
Antoine Piau ◽  
Claude Vautier ◽  
Adelaïde De Mauleon ◽  
Achille Tchalla ◽  
Pierre Rumeau ◽  
...  
Keyword(s):  
Long Term Care ◽  
Health Workers ◽  
Neuropsychiatric Symptoms ◽  
Term Care ◽  
Care Facilities

Barriers to Running Therapy Groups in Long-Term Care Facilities

2006 ◽  
Author(s):  
Jeremy Sharp ◽  
Kate L. Martin ◽  
Kate Martin
Keyword(s):  
Long Term Care ◽  
Term Care ◽  
Care Facilities
Sign in / Sign up

Export Citation Format

Share Document